Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help ...

Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval ... just those patients with carcinoma in situ, which represents a ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in ...

According to the latest statistics from the American Cancer Society, incidence rates of lung cancer are now higher in women than in men among people younger than 65 years. Overall, though, the news ...

1Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: John Paul Shen, Department of Colon and Rectal Surgery, The ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell ...

Danielle Fishel, star actress in Boy Meets World, recently opened up about her experience with ductal carcinoma in situ (DCIS), a non-invasive breast cancer. While celebrating the completion of her ...

Ductal carcinoma in situ is a precursor of breast cancer that is usually treated with surgery, radiation therapy, and estrogen blockade. A new study suggests that watchful waiting might be safe for ...

BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer. The FDA has granted ...